This meta-analysis showed that people with melanoma who underwent SNB had a significantly reduced risk of death from melanoma and recurrence compared with those who did not. These findings are consistent with the only published randomised controlled trial and were robust on sensitivity analyses, indicating that SNB confers true survival and recurrence benefits.
The Lancet Oncology published a clinical update in Oncology on 05 Mar 2026.
The item focuses on Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis.
Review the original article for the full source wording and details.